Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 8, 2007, Pages 1171-1178

  Taha, A S ^a   Angerson, W J ^b   Prasad, R ^a   Mccloskey, C ^a   Blatchford, O ^c  

^a CROSSHOUSE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANTICOAGULANT AGENT; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPYRIDAMOLE; ETODOLAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; ROFECOXIB; VALDECOXIB; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 34748917032     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03458.x     Document Type: Article

References (25)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999 340 : 1888 99.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004 54 : 8 29.
3. Mamadani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002 325 : 624 7.
4. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004 351 : 1709 11.
5. Krumhloz H, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx. BMJ 2007 334 : 120 3.
6. U.S. Food and Drug Administration. FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Withdraws the Product. Available at: http://www.fda.gov/bbs/topics/news/2004/NEW01122.html, accessed on 23 September 2006.
7. U.S. Food and Drug Administration. FDA Statement on the Halting of a Clinical Trial of the cox-2 Inhibitor Celebrex. Available at: http://www.fda.gov/bbs/topics/news/2004/NEW01144.html, accessed on 23 September 2006.
8. Medicines and Healthcare Products Regulatory Agency. Advice for Patients Following the Withdrawal of a Widely-used Painkiller/Anti-inflammatory - Vioxx. Available at: http://www.mhra.gov.uk/home/idcplg?IdcService= SS_GET_PAGE&useSecondary=tr., accessed on 19 September 2006.
9. Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O. Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a six-year analysis and comparison with non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2005 22 : 285 9.
10. Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O. Upper gastrointestinal mucosal abnormalities and blood loss complicating low-dose aspirin and antithrombotic therapy. Aliment Pharmacol Ther 2006 23 : 489 95.
11. Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O. Clinical outcome in upper gastrointestinal bleeding complicating low-dose aspirin and antithrombotic drugs. Aliment Pharmacol Ther 2006 24 : 633 6.
12. General Registrar for Scotland 2005. Available at: http://www.gro- scotland.gov.uk/files/05mype-cahb-t2.xls, accessed on 8 September 2006.
13. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper gastrointestinal haemorrhage. Lancet 2000 356 : 1316 21.
14. Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA study Group. Meloxicam Large Scale International Study Safety Assessment. Br J Rheumatol 1998 37 : 937 45.
15. Weideman RA, Kelly KC, Kazi S, et al. Risks of clinically significant upper gastrointestinal events with etocolac and naproxen: a historical cohort analysis. Gastroenterology 2004 127 : 1322 8.
16. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP for the MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007 369 : 465 73.
17. Laine L. Gastrointestinal bleeding with low-dose aspirin - what is the risk? Aliment Pharmacol Ther 2006 24 : 897 908.
18. Shuchman M. Delaying generic competition - corporate payoffs and the future of Plavix. N Engl J Med 2006 355 : 1297 300.
19. Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003 18 : 443 9.
20. Diener H-C, Bogousslavsky J, Brss LM, et al. Aspirin and clopigogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo controlled trial. Lancet 2004 364 : 331 7.
21. Sung JJY. Combining aspirin with antithrombotic agents. BMJ 2006 333 : 712 3.
22. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 2006 55 : 1731 8.
23. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006 333 : 726 8.
24. Andersen IB, Jorgensen T, Bonnevie O, Gronbaek M, Sorensen TI. Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcer: a population-based cohort study. Epidemiology 2000 11 : 434 9.
25. Sher L. Alcoholism and suicidal behaviour: a clinical overview. Acta Psychiatr Scand 2006 111 : 13 22.